NCT06894797 - Preoperative Chemoradiotherapy Combined With Consolidation or Induction NALIRIFOX in Rectal Cancer. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions

Locally Advanced Rectal Cancer

Interventions

RADIATION

Concurrent Chemoradiotherapy（Radiation + Capecitabine）

Capecitabine 825 mg/m\^2 Po BlD, Monday-Friday, on days of radiation treatment only, throughout the duration of RT Radiation：45-50Gy/25fractions/5 weeks，5fractions/week

DRUG

irinotecan hydrochloride liposome injection

Irinotecan hydrochloride liposome injection (50mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.

DRUG

Oxaliplatin

Oxaliplatin (60mg/m\^2) will be administered by intravenous infusion on day 1 in a 2-week treatment cycle.

DRUG

5-FU

5-FU (2400mg/m\^2) will be administered by intravenous infusion on 46h in a 2-week treatment cycle.

Trial Locations (1)

Unknown

RECRUITING

Beijing Cancer Hospital, Beijing